NVO Novo Nordisk

  1. Stocks
  2. Healthcare
  3. NYSE: NVO

Price (delayed)

$47.26

Market cap

$209.64B

P/E Ratio

11.8

Dividend/share

$1.8

EPS

26.23 DKK

Enterprise value

$224.24B

?
Relative Growth: Rel. Growth: 72
Relative Strength: Rel. Strength: 38
Relative Valuation: Rel. Valuation: 73
Relative Profitability: Rel. Profitability: 96

Novo Nordisk is a leading global health care company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage ...

Highlights
The stock's P/E is 61% less than its 5-year quarterly average of 30.4 and 6% less than its last 4 quarters average of 12.5
The equity has increased by 32% year-on-year and by 9% since the previous quarter
The debt has grown by 41% year-on-year but it has declined by 4.3% since the previous quarter
NVO's net income is up by 4.8% year-on-year but it is down by 4.5% since the previous quarter
NVO's gross margin is down by 3.9% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novonordisk.com
Peers: MRK BMY AMGN LLY

Key stats

What are the main financial stats of NVO

NVO stock price

How has the Novo Nordisk stock price performed over time
Intraday
2.81%
1 week
0.38%
1 month
-4.79%
1 year
-3.08%
YTD
-7.11%
QTD
-1.42%

Financial performance

How have Novo Nordisk's revenue and profit performed over time
Revenue
329.43B DKK
Gross profit
265.68B DKK
Operating income
142.1B DKK
Net income
116.44B DKK
Gross margin
80.6%
Net margin
35.3%
The revenue has grown by 6% year-on-year
The company's operating margin fell by 6% YoY and by 4.9% QoQ
The net margin has declined by 5% since the previous quarter
NVO's net income is up by 4.8% year-on-year but it is down by 4.5% since the previous quarter

Price vs fundamentals

How does NVO's price correlate with its fundamentals

Growth

What is Novo Nordisk's growth rate over time

Valuation

What is Novo Nordisk stock price valuation
NVO P/E details
P/E
11.8
P/B
6.22
P/S
4.18
EV/EBIT
9.87
EV/EBITDA
8.35
EV/Sales
4.46
The stock's P/E is 61% less than its 5-year quarterly average of 30.4 and 6% less than its last 4 quarters average of 12.5
Novo Nordisk's EPS has increased by 5% YoY but it has decreased by 4.4% from the previous quarter
NVO's price to book (P/B) is 72% lower than its 5-year quarterly average of 22.5 and 12% lower than its last 4 quarters average of 7.1
The equity has increased by 32% year-on-year and by 9% since the previous quarter
The P/S is 60% lower than the 5-year quarterly average of 10.4 and 2.8% lower than the last 4 quarters average of 4.3
The revenue has grown by 6% year-on-year

Efficiency

How efficient is Novo Nordisk business performance
The ROIC is down by 27% year-on-year and by 11% since the previous quarter
Novo Nordisk's ROE has decreased by 24% YoY and by 11% from the previous quarter
Novo Nordisk's return on assets has decreased by 13% YoY and by 9% QoQ
Novo Nordisk's ROS has decreased by 4.8% from the previous quarter

Dividends

What is NVO's dividend history
Dividend details
DPS
$1.8
Dividend yield
3.81%
Payout ratio
45%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Novo Nordisk financials performed over time
Novo Nordisk's total assets is 59% more than its total liabilities
NVO's quick ratio is up by 30% year-on-year and by 22% since the previous quarter
Novo Nordisk's total assets has increased by 23% YoY and by 6% from the previous quarter
The debt is 37% smaller than the equity
The debt has grown by 41% year-on-year but it has declined by 4.3% since the previous quarter
The equity has increased by 32% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.